Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934406 | 0.93 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1KDM4ELMNACYP2D6 | |
| SCHEMBL1936178 | 0.87 | S1PR1 (0.46) | SMN1; SMN2ALDH1A1KDM4EMCHR1 | |
| SCHEMBL1936450 | 0.85 | BCHE (0.50) | SMN1; SMN2ALDH1A1KDM4EBCHEPOLB | |
| SCHEMBL1936289 | 0.84 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1KDM4EBCHECYP2D6 | |
| SCHEMBL1936132 | 0.81 | MCHR1 (0.61) | ALDH1A1KDM4ECYP2D6CHRM1HTR2A | |
| SCHEMBL2276951 | 0.80 | HRH1 (0.55) | KDM4EBCHEHTR2A | |
| SCHEMBL16581996 | 0.79 | MC4R (0.50) | SMN1; SMN2ALDH1A1KDM4ECYP2D6CHRM1 | |
| SCHEMBL1934345 | 0.79 | MC4R (0.50) | SMN1; SMN2ALDH1A1KDM4ETDP1 | |
| SCHEMBL18841353 | 0.79 | KDM4E (0.67) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL18841354 | 0.79 | SIGMAR1 (0.51) | KDM4EBCHESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | SMN1; SMN2 4510/4885ALDH1A1 3283/4885KDM4E 2806/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | SMN1; SMN2 4544/4885ALDH1A1 3363/4885KDM4E 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.